[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-senomune-0257-fact-check-en":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":1363,"_id":1364,"_source":1365,"_file":1366,"_stem":1367,"_extension":1368},"\u002Fblog\u002Fen\u002Fsenomune-0257-fact-check","en",false,"","SenoMune-0257 fact-check: is it really a \"cancer-curing\" peptide?","This is general educational information, not medical advice and not a recommendation to get hold of anything or to use it. SenoMune-0257 is not available anywhere, and it has never been tested in a human being. There is no dose for it, and we do not name one.","Fact-check","tabler:zoom-question","#F2A93B","2026-10-26","October 2026","12 min","myPeptides Team","\u002Fassets\u002Fsenomune_hero.png",{"type":19,"children":20,"toc":1348},"root",[21,28,35,40,45,50,56,72,77,91,96,102,116,121,126,131,137,230,235,240,246,269,292,306,329,352,384,390,404,409,423,428,451,456,461,475,489,495,500,522,527,540,545,550,555,569,583,588,593,599,604,786,791,796,810,815,821,835,857,863,907,913,918,923,944,950],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":29,"props":30,"children":32},"h2",{"id":31},"the-short-version",[33],{"type":27,"value":34},"The short version",{"type":22,"tag":23,"props":36,"children":37},{},[38],{"type":27,"value":39},"On 24 October 2026, a post on X called SenoMune-0257 a \"cancer curing peptide\" with human trials by the end of the year. It rests on a press release from the US company Immorta Bio. That release describes a nine-amino-acid peptide meant to help the immune system remove aged cells. It contains no data and names no indication for it.",{"type":22,"tag":23,"props":41,"children":42},{},[43],{"type":27,"value":44},"The cancer angle started with the company: its chief scientific officer had called SenoMune-0257 a \"cancer immunotherapy\" the day before. The post turned this into \"cancer curing\", which no source supports.",{"type":22,"tag":23,"props":46,"children":47},{},[48],{"type":27,"value":49},"Our verdict: the post goes far beyond its sources. Nothing about SenoMune-0257 has been published, no human trial is registered, and its sequence is not public. The papers that do exist concern a different product called SenoVax, were done in mice and in cell culture and come from the company itself.",{"type":22,"tag":29,"props":51,"children":53},{"id":52},"the-post-that-went-viral",[54],{"type":27,"value":55},"The post that went viral",{"type":22,"tag":23,"props":57,"children":58},{},[59,61,70],{"type":27,"value":60},"The post came from the account ",{"type":22,"tag":62,"props":63,"children":67},"a",{"href":64,"rel":65},"https:\u002F\u002Fx.com\u002FItsPeptime\u002Fstatus\u002F2114006612188991733",[66],"nofollow",[68],{"type":27,"value":69},"@ItsPeptime",{"type":27,"value":71}," and had about 190,000 views, 5,100 likes and 457 reposts by 26 October. It reads: \"BREAKING: Cancer Curing peptide Senomune-0257 just completed pre-clinical studies successfully, promising human trials by end of year.\" It continues: \"This new peptide mimics cells which attack cancers, amplifying the bodies natural immune response!\"",{"type":22,"tag":23,"props":73,"children":74},{},[75],{"type":27,"value":76},"The account was created in January 2026. Its profile asks readers to buy \"99% pure USA peptides\" on its own website, which calls itself \"The American Peptide Vendor\".",{"type":22,"tag":23,"props":78,"children":79},{},[80,82,89],{"type":27,"value":81},"About 22 hours before that post, Immorta's chief scientific officer Thomas Ichim ",{"type":22,"tag":62,"props":83,"children":86},{"href":84,"rel":85},"https:\u002F\u002Fx.com\u002Fexosome\u002Fstatus\u002F2113677196380508376",[66],[87],{"type":27,"value":88},"wrote on X",{"type":27,"value":90}," that the company had \"discovered the first cancer immunotherapy that fights aging\". His post had about 153,000 views by 26 October.",{"type":22,"tag":23,"props":92,"children":93},{},[94],{"type":27,"value":95},"So the viral post did not invent the cancer angle, but it went one step further. A \"cancer immunotherapy that fights aging\" became \"cancer curing\", a word that appears in no company statement we could find.",{"type":22,"tag":29,"props":97,"children":99},{"id":98},"what-immorta-bio-actually-announced",[100],{"type":27,"value":101},"What Immorta Bio actually announced",{"type":22,"tag":23,"props":103,"children":104},{},[105,107,114],{"type":27,"value":106},"The ",{"type":22,"tag":62,"props":108,"children":111},{"href":109,"rel":110},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-pioneers-ai-designed-senolytic-immunotherapy-targeting-diseases-of-aging-302905700.html",[66],[112],{"type":27,"value":113},"press release of 12 October 2026",{"type":27,"value":115}," reports the \"completion of its planned preclinical studies\" for \"an AI-designed peptide immunotherapy\". Preclinical means laboratory work done before any testing in people. The product is \"a synthetic nine-amino-acid peptide designed to stimulate targeted immune responses against senescent cells\".",{"type":22,"tag":23,"props":117,"children":118},{},[119],{"type":27,"value":120},"According to the company, the peptide activates immune cells that kill other cells (cytotoxic T cells). These are said to remove senescent cells \"while sparing healthy cells under the conditions tested\". The release calls the product \"potentially universal, off-the-shelf\" and expects \"initial human evaluation\" before the end of 2026.",{"type":22,"tag":23,"props":122,"children":123},{},[124],{"type":27,"value":125},"The release gives no amino acid sequence, no target protein and no tissue type the peptide is matched to (its HLA restriction, explained below). It reports no numbers from any experiment and does not say whether animal studies were done.",{"type":22,"tag":23,"props":127,"children":128},{},[129],{"type":27,"value":130},"It names no trial site, no number of participants and no application to the US Food and Drug Administration (FDA). The release's own disclaimer states that SenoMune-0257 \"remains investigational, and its safety and efficacy have not been established in humans.\"",{"type":22,"tag":29,"props":132,"children":134},{"id":133},"line-by-line-the-post-against-the-sources",[135],{"type":27,"value":136},"Line by line: the post against the sources",{"type":22,"tag":138,"props":139,"children":140},"table",{},[141,160],{"type":22,"tag":142,"props":143,"children":144},"thead",{},[145],{"type":22,"tag":146,"props":147,"children":148},"tr",{},[149,155],{"type":22,"tag":150,"props":151,"children":152},"th",{},[153],{"type":27,"value":154},"The post says",{"type":22,"tag":150,"props":156,"children":157},{},[158],{"type":27,"value":159},"The sources say",{"type":22,"tag":161,"props":162,"children":163},"tbody",{},[164,178,191,204,217],{"type":22,"tag":146,"props":165,"children":166},{},[167,173],{"type":22,"tag":168,"props":169,"children":170},"td",{},[171],{"type":27,"value":172},"\"Cancer Curing\"",{"type":22,"tag":168,"props":174,"children":175},{},[176],{"type":27,"value":177},"No source says this. Ichim's own post calls it a \"cancer immunotherapy that fights aging\", which is a description, not a result. The press release names no cancer indication for SenoMune-0257 and reports no cancer data.",{"type":22,"tag":146,"props":179,"children":180},{},[181,186],{"type":22,"tag":168,"props":182,"children":183},{},[184],{"type":27,"value":185},"\"completed pre-clinical studies successfully\"",{"type":22,"tag":168,"props":187,"children":188},{},[189],{"type":27,"value":190},"The release reports \"completion of its planned preclinical studies\". It does not say \"successfully\" and shows no results.",{"type":22,"tag":146,"props":192,"children":193},{},[194,199],{"type":22,"tag":168,"props":195,"children":196},{},[197],{"type":27,"value":198},"\"promising human trials by end of year\"",{"type":22,"tag":168,"props":200,"children":201},{},[202],{"type":27,"value":203},"The release says \"initial human evaluation anticipated before year-end\". No trial is registered.",{"type":22,"tag":146,"props":205,"children":206},{},[207,212],{"type":22,"tag":168,"props":208,"children":209},{},[210],{"type":27,"value":211},"\"mimics cells which attack cancers\"",{"type":22,"tag":168,"props":213,"children":214},{},[215],{"type":27,"value":216},"No source says this. According to the release, the peptide stimulates T cells against senescent cells. It does not imitate any cell.",{"type":22,"tag":146,"props":218,"children":219},{},[220,225],{"type":22,"tag":168,"props":221,"children":222},{},[223],{"type":27,"value":224},"\"amplifying the bodies natural immune response\"",{"type":22,"tag":168,"props":226,"children":227},{},[228],{"type":27,"value":229},"Not in these words. The release uses the phrase \"restore the immune system's ability\".",{"type":22,"tag":23,"props":231,"children":232},{},[233],{"type":27,"value":234},"Two lines matter most. For \"cancer curing\", no cancer data on this peptide have been published, whether from patients, mice or cells in a dish. The company reports laboratory work, but no numbers. The cancer results this company has published come from its older product, SenoVax, in mice.",{"type":22,"tag":23,"props":236,"children":237},{},[238],{"type":27,"value":239},"\"Mimics cells\" gets the mechanism wrong. As described by the company, the peptide is a short protein fragment that shows T cells what to attack, not a copy of a cell.",{"type":22,"tag":29,"props":241,"children":243},{"id":242},"what-senescent-cells-are-and-why-researchers-want-to-remove-them",[244],{"type":27,"value":245},"What senescent cells are, and why researchers want to remove them",{"type":22,"tag":23,"props":247,"children":248},{},[249,251,258,260,267],{"type":27,"value":250},"Most cells in the body divide for a while and then stop (",{"type":22,"tag":62,"props":252,"children":255},{"href":253,"rel":254},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F13905658\u002F",[66],[256],{"type":27,"value":257},"Hayflick and Moorhead, 1961",{"type":27,"value":259},"). Cells that have permanently stopped dividing but do not die are called senescent cells, or \"zombie cells\" in popular writing. They release inflammatory signals (",{"type":22,"tag":62,"props":261,"children":264},{"href":262,"rel":263},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F19053174\u002F",[66],[265],{"type":27,"value":266},"Coppé et al., 2008",{"type":27,"value":268},") and build up with age.",{"type":22,"tag":23,"props":270,"children":271},{},[272,274,281,283,290],{"type":27,"value":273},"Removing them helped in mice. In 2011, ",{"type":22,"tag":62,"props":275,"children":278},{"href":276,"rel":277},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22048312\u002F",[66],[279],{"type":27,"value":280},"Baker and colleagues",{"type":27,"value":282}," genetically removed senescent cells in mice that age unusually fast, and age-related changes appeared later. In 2016, the same group ",{"type":22,"tag":62,"props":284,"children":287},{"href":285,"rel":286},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26840489\u002F",[66],[288],{"type":27,"value":289},"did this in normal mice",{"type":27,"value":291}," from the age of one year. Their median lifespan, the age by which half of them had died, increased, and tumours appeared later.",{"type":22,"tag":23,"props":293,"children":294},{},[295,297,304],{"type":27,"value":296},"In 2018, ",{"type":22,"tag":62,"props":298,"children":301},{"href":299,"rel":300},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29988130\u002F",[66],[302],{"type":27,"value":303},"Xu and colleagues",{"type":27,"value":305}," gave old mice two drugs, dasatinib and quercetin. Survival after the start of treatment increased by 36%.",{"type":22,"tag":23,"props":307,"children":308},{},[309,311,318,320,327],{"type":27,"value":310},"Results in humans are less clear. A ",{"type":22,"tag":62,"props":312,"children":315},{"href":313,"rel":314},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30616998\u002F",[66],[316],{"type":27,"value":317},"pilot study",{"type":27,"value":319}," of the drugs in 14 people with a lung disease (idiopathic pulmonary fibrosis) improved physical function but not lung function. It had no comparison group. In August 2020, UNITY Biotechnology ",{"type":22,"tag":62,"props":321,"children":324},{"href":322,"rel":323},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1463361\u002F000119312520222493\u002Fd28349dex991.htm",[66],[325],{"type":27,"value":326},"reported",{"type":27,"value":328}," that UBX0101 had done no better than placebo in a trial with 183 knee osteoarthritis patients.",{"type":22,"tag":23,"props":330,"children":331},{},[332,334,341,343,350],{"type":27,"value":333},"Other groups have turned the immune system against senescent cells in mice. They used engineered immune cells (",{"type":22,"tag":62,"props":335,"children":338},{"href":336,"rel":337},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32555459\u002F",[66],[339],{"type":27,"value":340},"Amor et al., 2020",{"type":27,"value":342},") or a vaccine against the senescence protein GPNMB (",{"type":22,"tag":62,"props":344,"children":347},{"href":345,"rel":346},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs43587-021-00151-2",[66],[348],{"type":27,"value":349},"Suda et al., 2021",{"type":27,"value":351},"). Both papers name the protein they target. Immorta has not done so.",{"type":22,"tag":23,"props":353,"children":354},{},[355,357,364,366,373,375,382],{"type":27,"value":356},"Cancer complicates the story. Senescence is one of the body's brakes on tumours. The immune system can clear such cells, as ",{"type":22,"tag":62,"props":358,"children":361},{"href":359,"rel":360},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22080947\u002F",[66],[362],{"type":27,"value":363},"Kang and colleagues",{"type":27,"value":365}," showed for pre-cancerous liver cells. Yet signals from senescent cells can also help tumours grow (",{"type":22,"tag":62,"props":367,"children":370},{"href":368,"rel":369},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11593017\u002F",[66],[371],{"type":27,"value":372},"Krtolica et al., 2001",{"type":27,"value":374},"; ",{"type":22,"tag":62,"props":376,"children":379},{"href":377,"rel":378},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23140366\u002F",[66],[380],{"type":27,"value":381},"Campisi, 2013",{"type":27,"value":383},"). Clearing them is not the same as curing cancer.",{"type":22,"tag":29,"props":385,"children":387},{"id":386},"what-nine-amino-acids-tells-you",[388],{"type":27,"value":389},"What \"nine amino acids\" tells you",{"type":22,"tag":23,"props":391,"children":392},{},[393,395,402],{"type":27,"value":394},"Nearly every cell carries display molecules on its surface (MHC class I) that show the immune system short protein fragments from inside the cell. These fragments are usually 8 to 10 amino acids long (",{"type":22,"tag":62,"props":396,"children":399},{"href":397,"rel":398},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28367149\u002F",[66],[400],{"type":27,"value":401},"Wieczorek et al., 2017",{"type":27,"value":403},"). T cells check them and attack cells that show a suspicious one.",{"type":22,"tag":23,"props":405,"children":406},{},[407],{"type":27,"value":408},"From what has been disclosed, SenoMune-0257 therefore looks like a classic peptide vaccine: it shows the immune system a fragment to look for. That raises two problems.",{"type":22,"tag":23,"props":410,"children":411},{},[412,414,421],{"type":27,"value":413},"The first is tissue type. In humans, these display molecules are called HLA, and their variants differ from person to person. A given nine-amino-acid fragment usually fits only certain variants. Immorta's ",{"type":22,"tag":62,"props":415,"children":418},{"href":416,"rel":417},"https:\u002F\u002Fpatents.google.com\u002Fpatent\u002FWO2025226744A1\u002Fen",[66],[419],{"type":27,"value":420},"patent application",{"type":27,"value":422}," on its cell-based approach reviews studies of this kind, for example one using \"HLA-A*0201-restricted peptides\".",{"type":22,"tag":23,"props":424,"children":425},{},[426],{"type":27,"value":427},"Immorta has not published which HLA molecule SenoMune-0257 binds to.",{"type":22,"tag":23,"props":429,"children":430},{},[431,433,440,442,449],{"type":27,"value":432},"As an example, take HLA-A*02:01, among the most common variants. According to the ",{"type":22,"tag":62,"props":434,"children":437},{"href":435,"rel":436},"https:\u002F\u002Fwww.allelefrequencies.net\u002Fhla\u002Fclassical-allele-frequency-search\u002F?allele=A*02:01",[66],[438],{"type":27,"value":439},"Allele Frequency Net Database",{"type":27,"value":441}," (",{"type":22,"tag":62,"props":443,"children":446},{"href":444,"rel":445},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F31722398\u002F",[66],[447],{"type":27,"value":448},"Gonzalez-Galarza et al., 2020",{"type":27,"value":450},"), it makes up about 28% of gene copies in large European registries. Among African Americans it is about 12%, and among Chinese donors in the US registry (NMDP) about 9%.",{"type":22,"tag":23,"props":452,"children":453},{},[454],{"type":27,"value":455},"Everyone carries two copies of each HLA gene, one from each parent. As a rough calculation, about half of people of European ancestry therefore carry at least one copy (48%). So do about one in four African Americans (23%) and one in five Chinese donors (18%).",{"type":22,"tag":23,"props":457,"children":458},{},[459],{"type":27,"value":460},"Even if SenoMune-0257 were matched to this variant, about half of Europeans would not carry it, which is hard to reconcile with \"universal\". A peptide can sometimes fit several related variants and reach more people, but without the sequence this cannot be judged.",{"type":22,"tag":23,"props":462,"children":463},{},[464,466,473],{"type":27,"value":465},"The second problem is how peptide vaccines against cancer have performed so far. In 2004, ",{"type":22,"tag":62,"props":467,"children":470},{"href":468,"rel":469},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F15340416\u002F",[66],[471],{"type":27,"value":472},"Rosenberg, Yang and Restifo",{"type":27,"value":474}," reviewed their own cancer vaccine trials in 440 patients: \"the objective response rate was low (2.6%)\". In fewer than three patients in a hundred did the tumour measurably shrink.",{"type":22,"tag":23,"props":476,"children":477},{},[478,480,487],{"type":27,"value":479},"Immorta made a related point in a ",{"type":22,"tag":62,"props":481,"children":484},{"href":482,"rel":483},"https:\u002F\u002Fdoi.org\u002F10.15406\u002Fjsrt.2024.09.00169",[66],[485],{"type":27,"value":486},"2024 review",{"type":27,"value":488},": \"single-antigen approaches leave open the possibility of immune editing and immune escape\". Put simply, if a vaccine trains the immune system on only one target, cells that stop displaying it can escape. SenoMune-0257 is such a single peptide.",{"type":22,"tag":29,"props":490,"children":492},{"id":491},"what-has-been-published-so-far",[493],{"type":27,"value":494},"What has been published so far",{"type":22,"tag":23,"props":496,"children":497},{},[498],{"type":27,"value":499},"We found no paper, preprint or patent on SenoMune-0257. A literature search for the name turned up only an unrelated cosmetic ingredient sold under the identical name Senomune (a green-tea root extract). Patent applications become public about 18 months after filing, so a recent one could still be invisible. Everything Immorta has published concerns its earlier product, SenoVax.",{"type":22,"tag":23,"props":501,"children":502},{},[503,505,512,514,520],{"type":27,"value":504},"In the ",{"type":22,"tag":62,"props":506,"children":509},{"href":507,"rel":508},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-025-07393-3",[66],[510],{"type":27,"value":511},"first SenoVax paper",{"type":27,"value":513},", from November 2025 in the ",{"type":22,"tag":515,"props":516,"children":517},"em",{},[518],{"type":27,"value":519},"Journal of Translational Medicine",{"type":27,"value":521},", SenoVax was a cell product, not a peptide. Immune cells were loaded with material from cells that had been made senescent in the lab with the chemotherapy drug doxorubicin.",{"type":22,"tag":23,"props":523,"children":524},{},[525],{"type":27,"value":526},"The mice carried transplanted lung, brain, pancreatic or breast tumours, with 10 animals per group. Tumours grew more slowly, and one type of T cell (CD8+) could pass the protection on. The text gives no percentages and no survival data. The number of senescent cells in tissue was not measured; the authors leave that to \"future studies\".",{"type":22,"tag":23,"props":528,"children":529},{},[530,531,538],{"type":27,"value":106},{"type":22,"tag":62,"props":532,"children":535},{"href":533,"rel":534},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-026-08221-y",[66],[536],{"type":27,"value":537},"second paper",{"type":27,"value":539},", from June 2026, describes SenoVax as a vaccine formulation \"comprising adjuvanted peptides derived from senescence-associated proteins\". Under the same name, the two papers describe two different products.",{"type":22,"tag":23,"props":541,"children":542},{},[543],{"type":27,"value":544},"Here the mice either had chemically induced liver damage (CCl₄) or received doxorubicin as a model of accelerated ageing. The doxorubicin model had five groups of 10: saline only, doxorubicin alone, or doxorubicin plus SenoVax, Immorta's stem cell product or both.",{"type":22,"tag":23,"props":546,"children":547},{},[548],{"type":27,"value":549},"In the liver damage model, the combination lowered two liver enzymes in the blood (AST and ALT) by 58 to 62%. Each treatment on its own lowered them by 32 to 40%.",{"type":22,"tag":23,"props":551,"children":552},{},[553],{"type":27,"value":554},"The \"lifespan\" result needs careful reading. According to a figure, the mice received doxorubicin \"5 mg\u002Fkg three times per week … until death\". What was measured was survival under continuous chemotherapy, not natural lifespan. All mice given doxorubicin alone had died by day 30. With the combination, 50% were alive on day 35 and 20% on day 40.",{"type":22,"tag":23,"props":556,"children":557},{},[558,560,567],{"type":27,"value":559},"Two letters to the journal have questioned the work. ",{"type":22,"tag":62,"props":561,"children":564},{"href":562,"rel":563},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-026-09014-z",[66],[565],{"type":27,"value":566},"Chen and Sun",{"type":27,"value":568}," wrote in October 2026 that \"survival during ongoing doxorubicin exposure should not be described as lifespan extension\". They also point out that the methods give doxorubicin at 2 mg\u002Fkg once a week, while the figures state 5 mg\u002Fkg three times a week.",{"type":22,"tag":23,"props":570,"children":571},{},[572,574,581],{"type":27,"value":573},"The second letter, by ",{"type":22,"tag":62,"props":575,"children":578},{"href":576,"rel":577},"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12967-026-07820-z",[66],[579],{"type":27,"value":580},"Xie and colleagues",{"type":27,"value":582},", concerns the first paper. It is friendly in tone but asks about long-term safety: \"The immune damage of physiological sites (e.g. sites of tissue repair) was not investigated.\"",{"type":22,"tag":23,"props":584,"children":585},{},[586],{"type":27,"value":587},"The second paper also reports effect sizes (Cohen's d), a measure of how strongly two groups differ. A value of 0.8 is conventionally already considered large. Here the average effect sizes reach up to 27, and single values up to 55. Differences this large call for independent replication.",{"type":22,"tag":23,"props":589,"children":590},{},[591],{"type":27,"value":592},"Both papers state that publication \"was funded by Immorta Bio Inc.\". Three authors, including Ichim, are listed as management and shareholders of the company. That is properly disclosed, and it means that all published SenoVax data come from the company itself.",{"type":22,"tag":29,"props":594,"children":596},{"id":595},"announced-versus-done",[597],{"type":27,"value":598},"Announced versus done",{"type":22,"tag":23,"props":600,"children":601},{},[602],{"type":27,"value":603},"Since 2024, Immorta has repeatedly announced steps toward human trials.",{"type":22,"tag":138,"props":605,"children":606},{},[607,623],{"type":22,"tag":142,"props":608,"children":609},{},[610],{"type":22,"tag":146,"props":611,"children":612},{},[613,618],{"type":22,"tag":150,"props":614,"children":615},{},[616],{"type":27,"value":617},"Date",{"type":22,"tag":150,"props":619,"children":620},{},[621],{"type":27,"value":622},"What the company said",{"type":22,"tag":161,"props":624,"children":625},{},[626,644,662,680,698,716,734,752,768],{"type":22,"tag":146,"props":627,"children":628},{},[629,639],{"type":22,"tag":168,"props":630,"children":631},{},[632],{"type":22,"tag":62,"props":633,"children":636},{"href":634,"rel":635},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-files-investigational-new-drug-application-for-first-in-class-senolytic-immunotherapy-senovax-for-treatment-of-advanced-lung-cancer-302207491.html",[66],[637],{"type":27,"value":638},"July 2024",{"type":22,"tag":168,"props":640,"children":641},{},[642],{"type":27,"value":643},"Application to start human trials (IND) filed for SenoVax in advanced lung cancer, file number 30745. SenoVax is then a cell product made from the patient's own cells.",{"type":22,"tag":146,"props":645,"children":646},{},[647,657],{"type":22,"tag":168,"props":648,"children":649},{},[650],{"type":22,"tag":62,"props":651,"children":654},{"href":652,"rel":653},"https:\u002F\u002Fwww.immortabio.com\u002Fnews\u002Fdiseases-aging-thomas-ichim",[66],[655],{"type":27,"value":656},"October 2024",{"type":22,"tag":168,"props":658,"children":659},{},[660],{"type":27,"value":661},"Goal: \"complete the Phase I\u002FIIa trial by Q3 2025\".",{"type":22,"tag":146,"props":663,"children":664},{},[665,675],{"type":22,"tag":168,"props":666,"children":667},{},[668],{"type":22,"tag":62,"props":669,"children":672},{"href":670,"rel":671},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-reports-preclinical-activity-of-senolytic-immunotherapy-senovax-in-a-chronic-traumatic-encephalopathy-cte-model-302565883.html",[66],[673],{"type":27,"value":674},"September 2025",{"type":22,"tag":168,"props":676,"children":677},{},[678],{"type":27,"value":679},"A manufacturing run is \"the remaining step prior to IND clearance\".",{"type":22,"tag":146,"props":681,"children":682},{},[683,693],{"type":22,"tag":168,"props":684,"children":685},{},[686],{"type":22,"tag":62,"props":687,"children":690},{"href":688,"rel":689},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-reports-reduction-of-tumors-in-validated-models-of-lung-brain-pancreatic-and-breast-cancers-using-anti-aging-vaccine-senovax-302633350.html",[66],[691],{"type":27,"value":692},"December 2025",{"type":22,"tag":168,"props":694,"children":695},{},[696],{"type":27,"value":697},"\"completing the required GMP manufacturing run to enable initiation\".",{"type":22,"tag":146,"props":699,"children":700},{},[701,711],{"type":22,"tag":168,"props":702,"children":703},{},[704],{"type":22,"tag":62,"props":705,"children":708},{"href":706,"rel":707},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-doubles-mouse-lifespan-using-combination-senolytic-and-regenerative-therapy-in-validated-aging-models-302656482.html",[66],[709],{"type":27,"value":710},"January 2026",{"type":22,"tag":168,"props":712,"children":713},{},[714],{"type":27,"value":715},"\"Doubles Mouse Lifespan\"; SenoVax \"currently under FDA review\".",{"type":22,"tag":146,"props":717,"children":718},{},[719,729],{"type":22,"tag":168,"props":720,"children":721},{},[722],{"type":22,"tag":62,"props":723,"children":726},{"href":724,"rel":725},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-demonstrates-dramatic-lifespan-extension-in-aging-mouse-models-research-accepted-for-presentation-at-aais-immunology2026-302711019.html",[66],[727],{"type":27,"value":728},"March 2026",{"type":22,"tag":168,"props":730,"children":731},{},[732],{"type":27,"value":733},"Ageing mouse models: \"~73% increase in mean survival and ~84% extension of median lifespan\".",{"type":22,"tag":146,"props":735,"children":736},{},[737,747],{"type":22,"tag":168,"props":738,"children":739},{},[740],{"type":22,"tag":62,"props":741,"children":744},{"href":742,"rel":743},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fimmorta-bio-publishes-over-70-increased-longevity-in-aging-animals-by-its-patented-therapeutic-combination-302798055.html",[66],[745],{"type":27,"value":746},"June 2026",{"type":22,"tag":168,"props":748,"children":749},{},[750],{"type":27,"value":751},"\"over 70% lifespan extension\", as the second paper is published.",{"type":22,"tag":146,"props":753,"children":754},{},[755,763],{"type":22,"tag":168,"props":756,"children":757},{},[758],{"type":22,"tag":62,"props":759,"children":761},{"href":109,"rel":760},[66],[762],{"type":27,"value":14},{"type":22,"tag":168,"props":764,"children":765},{},[766],{"type":27,"value":767},"SenoMune-0257: preclinical studies complete, \"initial human evaluation anticipated before year-end\".",{"type":22,"tag":146,"props":769,"children":770},{},[771,781],{"type":22,"tag":168,"props":772,"children":773},{},[774],{"type":22,"tag":62,"props":775,"children":778},{"href":776,"rel":777},"https:\u002F\u002Fclinicaltrials.gov\u002Fapi\u002Fv2\u002Fstudies?query.term=SenoVax",[66],[779],{"type":27,"value":780},"26 October 2026",{"type":22,"tag":168,"props":782,"children":783},{},[784],{"type":27,"value":785},"ClinicalTrials.gov lists 0 studies for SenoVax, SenoMune or Immorta.",{"type":22,"tag":23,"props":787,"children":788},{},[789],{"type":27,"value":790},"For its accelerated-ageing model, the company's figure moved from \"doubled\" to 73% and 84%, then to \"over 70%\". The paper itself gives no percentage for lifespan extension.",{"type":22,"tag":23,"props":792,"children":793},{},[794],{"type":27,"value":795},"The IND number 30745 is a file number the FDA assigns to an application, not an approval. In January 2026, the company described the application as under FDA review; whether it has since been cleared is not publicly visible.",{"type":22,"tag":23,"props":797,"children":798},{},[799,801,808],{"type":27,"value":800},"Immorta's filings with the US Securities and Exchange Commission (",{"type":22,"tag":62,"props":802,"children":805},{"href":803,"rel":804},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F2102665\u002F000210266526000002\u002FxslFormDX01\u002Fprimary_doc.xml",[66],[806],{"type":27,"value":807},"Form D",{"type":27,"value":809},") describe a private company without revenue, incorporated in Delaware in 2023. Since November 2024, it has been raising money from private investors.",{"type":22,"tag":23,"props":811,"children":812},{},[813],{"type":27,"value":814},"The latest filing (16 October 2026) reports USD 612,503 sold to six investors, out of up to USD 5 million. An earlier one (8 January 2026) reported USD 450,000 out of USD 500,000.",{"type":22,"tag":29,"props":816,"children":818},{"id":817},"can-you-buy-senomune-0257",[819],{"type":27,"value":820},"Can you buy SenoMune-0257?",{"type":22,"tag":23,"props":822,"children":823},{},[824,826,833],{"type":27,"value":825},"No. Its sequence has not been published, so anyone offering a product under this name cannot know what they are making. A web search on 26 October 2026 found no shop listing it, though it did not cover messaging channels. A ",{"type":22,"tag":62,"props":827,"children":830},{"href":828,"rel":829},"https:\u002F\u002Fdoi.org\u002F10.1111\u002Fexd.70366",[66],[831],{"type":27,"value":832},"cosmetic ingredient",{"type":27,"value":834}," made from green-tea root carries the same name but is unrelated.",{"type":22,"tag":23,"props":836,"children":837},{},[838,840,847,849,855],{"type":27,"value":839},"You may also have seen FOXO4-DRI in this context, a peptide designed to make senescent cells die off. In a 2017 study by ",{"type":22,"tag":62,"props":841,"children":844},{"href":842,"rel":843},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28340339\u002F",[66],[845],{"type":27,"value":846},"Baar and colleagues",{"type":27,"value":848},", it improved fitness, fur and kidney function in old mice. There has never been a human study. Our ",{"type":22,"tag":62,"props":850,"children":852},{"href":851},"\u002Fpeptides\u002Ffoxo4-dri",[853],{"type":27,"value":854},"FOXO4-DRI monograph",{"type":27,"value":856}," sets out what is known and what is not.",{"type":22,"tag":29,"props":858,"children":860},{"id":859},"how-to-check-a-breakthrough-post-yourself",[861],{"type":27,"value":862},"How to check a \"breakthrough\" post yourself",{"type":22,"tag":864,"props":865,"children":866},"ul",{},[867,873,878,883,897,902],{"type":22,"tag":868,"props":869,"children":870},"li",{},[871],{"type":27,"value":872},"Find the primary source, such as the press release or the study, and read what it says.",{"type":22,"tag":868,"props":874,"children":875},{},[876],{"type":27,"value":877},"Check whether there is a peer-reviewed paper or only a press release, which the company writes itself.",{"type":22,"tag":868,"props":879,"children":880},{},[881],{"type":27,"value":882},"Find out whether the results come from people, from animals or from cells in a dish.",{"type":22,"tag":868,"props":884,"children":885},{},[886,888,895],{"type":27,"value":887},"Search ",{"type":22,"tag":62,"props":889,"children":892},{"href":890,"rel":891},"https:\u002F\u002Fclinicaltrials.gov\u002F",[66],[893],{"type":27,"value":894},"ClinicalTrials.gov",{"type":27,"value":896}," for the drug and the company, where human trials are usually registered.",{"type":22,"tag":868,"props":898,"children":899},{},[900],{"type":27,"value":901},"Read the funding and conflict-of-interest statements to see who paid for the work.",{"type":22,"tag":868,"props":903,"children":904},{},[905],{"type":27,"value":906},"Look at who is spreading the news and whether they sell something related.",{"type":22,"tag":29,"props":908,"children":910},{"id":909},"bottom-line",[911],{"type":27,"value":912},"Bottom line",{"type":22,"tag":23,"props":914,"children":915},{},[916],{"type":27,"value":917},"SenoMune-0257 is an announcement, not a result. There is a press release without data and a post by the company's scientist calling it a cancer immunotherapy. A shop-linked account then turned this into a cancer cure. The peptide has not been tested in people, and no trial is registered.",{"type":22,"tag":23,"props":919,"children":920},{},[921],{"type":27,"value":922},"Training the immune system to clear senescent cells is a serious field of research, with real results in mice and a mixed record in humans. Whether this peptide works will only be known once data are published and a registered trial reports results. Until then, it cannot be bought, and there is no dose for it.",{"type":22,"tag":23,"props":924,"children":925},{},[926,928,934,936,942],{"type":27,"value":927},"If you want the basics first, start with ",{"type":22,"tag":62,"props":929,"children":931},{"href":930},"\u002Fwhat-are-peptides",[932],{"type":27,"value":933},"what peptides are",{"type":27,"value":935},". If you are named here and believe a factual statement is wrong, please contact us through our ",{"type":22,"tag":62,"props":937,"children":939},{"href":938},"\u002Flegal-notice",[940],{"type":27,"value":941},"legal notice",{"type":27,"value":943},".",{"type":22,"tag":29,"props":945,"children":947},{"id":946},"sources",[948],{"type":27,"value":949},"Sources",{"type":22,"tag":864,"props":951,"children":952},{},[953,964,974,985,996,1007,1018,1029,1040,1051,1062,1073,1084,1095,1106,1117,1128,1139,1150,1161,1172,1183,1194,1205,1216,1227,1238,1249,1260,1271,1282,1293,1304,1315,1326,1337],{"type":22,"tag":868,"props":954,"children":955},{},[956,958],{"type":27,"value":957},"@ItsPeptime on X, 24 October 2026, ",{"type":22,"tag":62,"props":959,"children":961},{"href":64,"rel":960},[66],[962],{"type":27,"value":963},"Post on SenoMune-0257",{"type":22,"tag":868,"props":965,"children":966},{},[967,969],{"type":27,"value":968},"Thomas Ichim (@exosome) on X, 23 October 2026, ",{"type":22,"tag":62,"props":970,"children":972},{"href":84,"rel":971},[66],[973],{"type":27,"value":963},{"type":22,"tag":868,"props":975,"children":976},{},[977,979],{"type":27,"value":978},"Immorta Bio, 12 October 2026, ",{"type":22,"tag":62,"props":980,"children":982},{"href":109,"rel":981},[66],[983],{"type":27,"value":984},"Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging",{"type":22,"tag":868,"props":986,"children":987},{},[988,990],{"type":27,"value":989},"Immorta Bio, 26 July 2024, ",{"type":22,"tag":62,"props":991,"children":993},{"href":634,"rel":992},[66],[994],{"type":27,"value":995},"Immorta Bio Files IND for SenoVax for Advanced Lung Cancer",{"type":22,"tag":868,"props":997,"children":998},{},[999,1001],{"type":27,"value":1000},"Immorta Bio, 2 October 2024, ",{"type":22,"tag":62,"props":1002,"children":1004},{"href":652,"rel":1003},[66],[1005],{"type":27,"value":1006},"Diseases of Aging: Q&A with Dr. Thomas Ichim",{"type":22,"tag":868,"props":1008,"children":1009},{},[1010,1012],{"type":27,"value":1011},"Immorta Bio, 24 September 2025, ",{"type":22,"tag":62,"props":1013,"children":1015},{"href":670,"rel":1014},[66],[1016],{"type":27,"value":1017},"Preclinical Activity of SenoVax in a CTE Model",{"type":22,"tag":868,"props":1019,"children":1020},{},[1021,1023],{"type":27,"value":1022},"Immorta Bio, 4 December 2025, ",{"type":22,"tag":62,"props":1024,"children":1026},{"href":688,"rel":1025},[66],[1027],{"type":27,"value":1028},"Reduction of Tumors Using SenoVax",{"type":22,"tag":868,"props":1030,"children":1031},{},[1032,1034],{"type":27,"value":1033},"Immorta Bio, 8 January 2026, ",{"type":22,"tag":62,"props":1035,"children":1037},{"href":706,"rel":1036},[66],[1038],{"type":27,"value":1039},"Immorta Bio Doubles Mouse Lifespan",{"type":22,"tag":868,"props":1041,"children":1042},{},[1043,1045],{"type":27,"value":1044},"Immorta Bio, 11 March 2026, ",{"type":22,"tag":62,"props":1046,"children":1048},{"href":724,"rel":1047},[66],[1049],{"type":27,"value":1050},"Dramatic Lifespan Extension in Aging Mouse Models",{"type":22,"tag":868,"props":1052,"children":1053},{},[1054,1056],{"type":27,"value":1055},"Immorta Bio, 11 June 2026, ",{"type":22,"tag":62,"props":1057,"children":1059},{"href":742,"rel":1058},[66],[1060],{"type":27,"value":1061},"Over 70% Increased Longevity in Aging Animals",{"type":22,"tag":868,"props":1063,"children":1064},{},[1065,1067],{"type":27,"value":1066},"U.S. Securities and Exchange Commission, 16 October 2026, ",{"type":22,"tag":62,"props":1068,"children":1070},{"href":803,"rel":1069},[66],[1071],{"type":27,"value":1072},"Form D, Immorta Bio, Inc. (CIK 0002102665)",{"type":22,"tag":868,"props":1074,"children":1075},{},[1076,1078],{"type":27,"value":1077},"ClinicalTrials.gov, 26 October 2026, ",{"type":22,"tag":62,"props":1079,"children":1081},{"href":776,"rel":1080},[66],[1082],{"type":27,"value":1083},"Search for SenoVax (SenoMune and Immorta likewise 0 results)",{"type":22,"tag":868,"props":1085,"children":1086},{},[1087,1089],{"type":27,"value":1088},"Immorta Bio, 30 October 2025, ",{"type":22,"tag":62,"props":1090,"children":1092},{"href":416,"rel":1091},[66],[1093],{"type":27,"value":1094},"WO2025226744A1: Senescent cell targeting T cell responses",{"type":22,"tag":868,"props":1096,"children":1097},{},[1098,1100],{"type":27,"value":1099},"Ichim et al., Journal of Translational Medicine 2025, ",{"type":22,"tag":62,"props":1101,"children":1103},{"href":507,"rel":1102},[66],[1104],{"type":27,"value":1105},"Reduction of solid tumors by senescent cell immunization",{"type":22,"tag":868,"props":1107,"children":1108},{},[1109,1111],{"type":27,"value":1110},"Ichim et al., Journal of Translational Medicine 2026, ",{"type":22,"tag":62,"props":1112,"children":1114},{"href":533,"rel":1113},[66],[1115],{"type":27,"value":1116},"Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan",{"type":22,"tag":868,"props":1118,"children":1119},{},[1120,1122],{"type":27,"value":1121},"Chen and Sun, Journal of Translational Medicine 2026, ",{"type":22,"tag":62,"props":1123,"children":1125},{"href":562,"rel":1124},[66],[1126],{"type":27,"value":1127},"Treatment benefit does not establish senolysis or lifespan extension",{"type":22,"tag":868,"props":1129,"children":1130},{},[1131,1133],{"type":27,"value":1132},"Xie et al., Journal of Translational Medicine 2026, ",{"type":22,"tag":62,"props":1134,"children":1136},{"href":576,"rel":1135},[66],[1137],{"type":27,"value":1138},"Letter to the editor: clinical translation of senolytic immunotherapy: critical considerations for SenoVax and beyond",{"type":22,"tag":868,"props":1140,"children":1141},{},[1142,1144],{"type":27,"value":1143},"Veklych et al., Journal of Stem Cell Research & Therapeutics 2024, ",{"type":22,"tag":62,"props":1145,"children":1147},{"href":482,"rel":1146},[66],[1148],{"type":27,"value":1149},"Can senolysis be used to overcome tumor immune evasion?",{"type":22,"tag":868,"props":1151,"children":1152},{},[1153,1155],{"type":27,"value":1154},"Hayflick and Moorhead, Experimental Cell Research 1961, ",{"type":22,"tag":62,"props":1156,"children":1158},{"href":253,"rel":1157},[66],[1159],{"type":27,"value":1160},"The serial cultivation of human diploid cell strains",{"type":22,"tag":868,"props":1162,"children":1163},{},[1164,1166],{"type":27,"value":1165},"Coppé et al., PLoS Biology 2008, ",{"type":22,"tag":62,"props":1167,"children":1169},{"href":262,"rel":1168},[66],[1170],{"type":27,"value":1171},"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor",{"type":22,"tag":868,"props":1173,"children":1174},{},[1175,1177],{"type":27,"value":1176},"Baker et al., Nature 2011, ",{"type":22,"tag":62,"props":1178,"children":1180},{"href":276,"rel":1179},[66],[1181],{"type":27,"value":1182},"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders",{"type":22,"tag":868,"props":1184,"children":1185},{},[1186,1188],{"type":27,"value":1187},"Baker et al., Nature 2016, ",{"type":22,"tag":62,"props":1189,"children":1191},{"href":285,"rel":1190},[66],[1192],{"type":27,"value":1193},"Naturally occurring p16Ink4a-positive cells shorten healthy lifespan",{"type":22,"tag":868,"props":1195,"children":1196},{},[1197,1199],{"type":27,"value":1198},"Xu et al., Nature Medicine 2018, ",{"type":22,"tag":62,"props":1200,"children":1202},{"href":299,"rel":1201},[66],[1203],{"type":27,"value":1204},"Senolytics improve physical function and increase lifespan in old age",{"type":22,"tag":868,"props":1206,"children":1207},{},[1208,1210],{"type":27,"value":1209},"Justice et al., EBioMedicine 2019, ",{"type":22,"tag":62,"props":1211,"children":1213},{"href":313,"rel":1212},[66],[1214],{"type":27,"value":1215},"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study",{"type":22,"tag":868,"props":1217,"children":1218},{},[1219,1221],{"type":27,"value":1220},"UNITY Biotechnology, 17 August 2020, ",{"type":22,"tag":62,"props":1222,"children":1224},{"href":322,"rel":1223},[66],[1225],{"type":27,"value":1226},"UBX0101 phase 2 12-week data (Form 8-K, Exhibit 99.1)",{"type":22,"tag":868,"props":1228,"children":1229},{},[1230,1232],{"type":27,"value":1231},"Amor et al., Nature 2020, ",{"type":22,"tag":62,"props":1233,"children":1235},{"href":336,"rel":1234},[66],[1236],{"type":27,"value":1237},"Senolytic CAR T cells reverse senescence-associated pathologies",{"type":22,"tag":868,"props":1239,"children":1240},{},[1241,1243],{"type":27,"value":1242},"Suda et al., Nature Aging 2021, ",{"type":22,"tag":62,"props":1244,"children":1246},{"href":345,"rel":1245},[66],[1247],{"type":27,"value":1248},"Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice",{"type":22,"tag":868,"props":1250,"children":1251},{},[1252,1254],{"type":27,"value":1253},"Kang et al., Nature 2011, ",{"type":22,"tag":62,"props":1255,"children":1257},{"href":359,"rel":1256},[66],[1258],{"type":27,"value":1259},"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development",{"type":22,"tag":868,"props":1261,"children":1262},{},[1263,1265],{"type":27,"value":1264},"Krtolica et al., PNAS 2001, ",{"type":22,"tag":62,"props":1266,"children":1268},{"href":368,"rel":1267},[66],[1269],{"type":27,"value":1270},"Senescent fibroblasts promote epithelial cell growth and tumorigenesis",{"type":22,"tag":868,"props":1272,"children":1273},{},[1274,1276],{"type":27,"value":1275},"Campisi, Annual Review of Physiology 2013, ",{"type":22,"tag":62,"props":1277,"children":1279},{"href":377,"rel":1278},[66],[1280],{"type":27,"value":1281},"Aging, cellular senescence, and cancer",{"type":22,"tag":868,"props":1283,"children":1284},{},[1285,1287],{"type":27,"value":1286},"Wieczorek et al., Frontiers in Immunology 2017, ",{"type":22,"tag":62,"props":1288,"children":1290},{"href":397,"rel":1289},[66],[1291],{"type":27,"value":1292},"MHC class I and MHC class II proteins: conformational plasticity in antigen presentation",{"type":22,"tag":868,"props":1294,"children":1295},{},[1296,1298],{"type":27,"value":1297},"Allele Frequency Net Database, 26 October 2026, ",{"type":22,"tag":62,"props":1299,"children":1301},{"href":435,"rel":1300},[66],[1302],{"type":27,"value":1303},"Allele report HLA-A*02:01",{"type":22,"tag":868,"props":1305,"children":1306},{},[1307,1309],{"type":27,"value":1308},"Gonzalez-Galarza et al., Nucleic Acids Research 2020, ",{"type":22,"tag":62,"props":1310,"children":1312},{"href":444,"rel":1311},[66],[1313],{"type":27,"value":1314},"Allele frequency net database (AFND) 2020 update",{"type":22,"tag":868,"props":1316,"children":1317},{},[1318,1320],{"type":27,"value":1319},"Rosenberg et al., Nature Medicine 2004, ",{"type":22,"tag":62,"props":1321,"children":1323},{"href":468,"rel":1322},[66],[1324],{"type":27,"value":1325},"Cancer immunotherapy: moving beyond current vaccines",{"type":22,"tag":868,"props":1327,"children":1328},{},[1329,1331],{"type":27,"value":1330},"Park et al., Experimental Dermatology 2026, ",{"type":22,"tag":62,"props":1332,"children":1334},{"href":828,"rel":1333},[66],[1335],{"type":27,"value":1336},"Plant-derived senolytic ingredient, Camellia sinensis root extract",{"type":22,"tag":868,"props":1338,"children":1339},{},[1340,1342],{"type":27,"value":1341},"Baar et al., Cell 2017, ",{"type":22,"tag":62,"props":1343,"children":1345},{"href":842,"rel":1344},[66],[1346],{"type":27,"value":1347},"Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging",{"title":7,"searchDepth":1349,"depth":1349,"links":1350},2,[1351,1352,1353,1354,1355,1356,1357,1358,1359,1360,1361,1362],{"id":31,"depth":1349,"text":34},{"id":52,"depth":1349,"text":55},{"id":98,"depth":1349,"text":101},{"id":133,"depth":1349,"text":136},{"id":242,"depth":1349,"text":245},{"id":386,"depth":1349,"text":389},{"id":491,"depth":1349,"text":494},{"id":595,"depth":1349,"text":598},{"id":817,"depth":1349,"text":820},{"id":859,"depth":1349,"text":862},{"id":909,"depth":1349,"text":912},{"id":946,"depth":1349,"text":949},"markdown","content:blog:en:senomune-0257-fact-check.md","content","blog\u002Fen\u002Fsenomune-0257-fact-check.md","blog\u002Fen\u002Fsenomune-0257-fact-check","md"]